E-cadherin在乳腺浸润性导管癌中的表达及临床意义

目的 探讨E-钙黏蛋白（E-cad）在乳腺浸润性导管癌中的表达及其与乳腺癌临床病理特征、淋巴结转移及预后的关系。方法 采用免疫组织化学 SP 法检测30例乳腺纤维腺瘤、450例乳腺浸润性导管癌组织中E-cad的表达，分析其表达与临床病理特征的关系， Kaplan-Meier法绘制生存曲线。结果E-cad在无淋巴结转移乳腺癌组织中阳性表达率为49.04％（77／157），在有淋巴结转移的乳腺癌组织中阳性表达率为29.69％（87／293），差异有统计学意义（P＜0.05）。E-cad表达与年龄、淋巴结转移、肿块大小、ER表达、分子分型及组织学分级有关（P＜0.05），而与肿瘤分期、是否绝经、HER-2及Ki-67表达情况无关。乳腺癌淋巴结转移组、三阴性乳腺癌组中E-cad阳性表达者5年生存率优于E-cad阴性表达者，差异有统计学意义（P＜0.05）。结论 E-cad表达与乳腺癌淋巴结转移关系密切，其亦可成为乳腺癌伴淋巴结转移者或三阴性乳腺癌预后的判断指标。

Expression and clinical significance of E-cadherin in invasive ductal carcinoma

Objective To investigate the expression of E-cadherin(E-cad) in invasive ductal carcinoma and its relationship with clinicopathological features, lymph node metastasis and prognosis.Methods Immunohistochemical SP method was used to detect the expression of E-cad in 30 cases of breast fibroadenoma and 450 cases of breast invasive ductal carcinoma.The relationship between its expression and clinical pathological features was analyzed.The survival curve was drawn by Kaplan-Meier method.Results The positive expression rate of E-cad in non-metastatic breast cancer tissues was 49.04% (77/157), which was significantly higher than that of E-cad in metastatic breast cancer(P<0.05).The expression of E-cad was correlated with age, lymph node metastasis, tumor size, ER expression, molecular type and histological grade (P<0.05), but not with tumor stage, the expression of HER-2 and Ki-67.The 5-year survival rate of patients with E-cad positive expression in breast cancer lymph node metastasis group and triple-negative breast cancer group was better than those with E-cad negative expression(P<0.05).Conclusion The expression of E-cad is closely related to the lymph node metastasis of breast cancer, and it may also be a prognostic indicator of breast cancer with lymph node metastasis or triple-negative breast cancer.